Headshot of Mark Wilson

Mark E. Wilson, Ph.D.


Title
Technology Specialist
Offices
San Diego
Phone Numbers
Email
[email protected]

Overview

Mark Wilson, Ph.D., spent nearly 20 years in small molecule drug discovery, where he produced three Investigational New Drug filings and multiple pre-clinical candidates.

Mark has extensive experience in all phases of the drug discovery process, including target selection, screening, lead discovery and optimization, drug metabolism and pharmacokinetics, and pharmacokinetics, and he is a named inventor on 14 issued patents. Leveraging his industry experience, Mark’s practice focuses on patent drafting and prosecution, performing patentability and clearance searches, and competitive portfolio analysis.

Mark was an NIH post-doctoral fellow at the University of California, Irvine, in the areas of synthetic organic and peptidomimetic chemistry.

Patents

  • Venkataiah Bollu, James Breitenbucher, Alan Kaplan, Robert Lemus, Andrew Lindstrom, Troy Vickers, Mark Wilson, James Zapf, Michael I. Weinhouse; U.S. P20140275531 A: Substituted Pyridine and Pyrazine Compounds as PDE4 Inhibitors.
  • Alan Ka plan, Terence Keenan, Michael Weinhouse, Mark Wilson, Andrew Lindstrom, William Ripka, and Mi Chen; WO/ 2012/ 040258: THERAPEUTIC PIPERAZINES.
  • Arnold, William D.; Bounaud, Pierre; Chen, Chixu; Eastman, Brian; Gosberg, Andreas; Gradl, Stefan N.; Hopkins, Stephanie; Li, Zhe; McDonald, Ian; Sprengeler, Paul A.; Steensma, Ruo W.; Wilson, Mark E.; US20070287711Al: Fused Ring Heterocycle Kinase Modulators.
  • Bounaud, Pierre -Yves; Hopkins, Stephanie A.; Jeffer son, Elizabeth Anne; Wilson, Mark E.; Wong, Melissa S.; Kanouni, Toufike; US20070173488Al: Pyrazolothiazole Protein Kinase Modulators.
  • Arnold, William D.; Ch en, Chixu; GradI, Stefan N.; Hopkins, Stephanie A.; Steensma, Ruo W.; Tomimoto, Masaki; Wilson, Mark E.; US20070117800Al: Pyrimidinyl-thiophene Kinase Modulators.
  • Arnold, William D.; Bounaud, Pierre; Gosberg, Andreas; Li, Zhe; McDonald, Ian; Steensma, Ruo W.; Wilson, Mark E.; US20070043068Al: Pyrrolo-pyridine Kinase Modulators.
  • Arnold, William D.; Gosberg, Andreas; Li, Zhe; Steensma, Ruo W.; Wilson, Mark E.; US20060035898Al: Fused ring Heterocycle Kinase Modulators.
  • Arnold, William D.; Bounaud, Pierre; Gosberg, Andreas; Li, Zhe; McDonald, Ian; Steensma, Ruo W.; Wilson, Mark E.; US20060030583Al: Pyrrolo-pyridine Kinase Modulators.
  • Cheng, Jie Fei; Chen, Mi; Arrhenius, Thomas; Wilson, Mark E.; Lopaschuk, Gary D.; Dyck, Jason R.; Serafimov, Rossy; US200500 32828Al: Piperidine Compounds Useful as Malonyl -CoA Decarboxylase Inhibitors.
  • Cheng, Jie Fei; Liu, Bin; Arrhenius, Thomas; Wilson, Mark E.; Nadzan, Alex M .; Lopaschuk, Gary D.; Dyck, Jason R.; Serafimov, Ross y; US20050032824Al: Cyanoguanidine-based Azole Compounds Useful as Malonyl­ CoA Decarboxylase Inhibitors.
  • Kafka, Mark D.; Wilson, Mark E.; Russell, Anna; Lopaschuk, Gary D.; Dyck, Jason R.; US20050026945Al: Cyanoamide Compounds Useful as Malonyl-CoA Decarboxylase Inhibitors.
  • Arrhenius, Thomas; Cheng, Jie Fei; Wilson, Mark E; Serafimov, Rossy; US20040092503Al : Azoles as Malonyl-coa Decarboxylase Inhibitors Useful as Metabolic Modulators.
  • Arrhenius, Thomas; Cheng, Jie Fei; Wilson, Mark E.; Serafimov, Rossy; Nishimoto, Masahiro; Wallace, David Mark; Tith, Sovouthy; Brown, Steve Joel; Harmon, Charles Stanford; US20040082564Al: Methods for Treating Metabolic Diseases Using Malonyl-CoA Decarboxylase Inhibitors.